NEWS Life Molecular Imaging Announces Start of the Phase 3 Histopathology Study “ADvance” for the Tau PET Tracer [18F]PI-2620 17 January 2023 LEARN MORE
NEWS Life Molecular Imaging and Jubilant Radiopharma announce Neuraceq® availability in Southeast United States 10 January 2023 LEARN MORE
NEWS Life Molecular Imaging announces presentation of new scientific data at the European Association of Nuclear Medicine annual meeting 2022 14 October 2022 LEARN MORE
NEWS Statement of Life Molecular Imaging on Eisai and Biogen announcing Positive Topline Results of their Phase 3 Clarity AD Study 28 September 2022 LEARN MORE
NEWS Life Molecular Imaging and Curium Pharma Announce the Start of Neuraceq® Production at Curium’s Blackrock Clinic in Dublin 29 August 2022 LEARN MORE
NEWS Life Molecular Imaging announces presentation of new scientific data at the Alzheimer’s Association International Conference 29 July 2022 LEARN MORE
NEWS Life Molecular Imaging and BIOKOSMOS SA Announce a Strategic Partnership for the Production and Supply of Neuraceq® in Greece, Bulgaria, North Macedonia and Albania 15th July 2022 LEARN MORE
NEWS Life Molecular Imaging and R2IBF Announce the First Commercial PET Scan of Florbetaben (18F) in Brazil May 31, 2022 LEARN MORE
NEWS DuChemBio Co., Ltd. & Life Molecular Imaging Announce Material Transfer And Clinical Supply Agreement for [18F]PI-2620 Tau PET Tracer August 17, 2021 LEARN MORE
NEWS Life Molecular Imaging Receives Orphan Drug Designations for its Tau Tracer PI-2620 as Diagnostic Tool for Progressive Supranuclear Palsy and Corticobasal Degeneration May 20, 2021 LEARN MORE
